Aethlon Medical Inc (AEMD) 0.1201 $AEMD
Aethlon Medical Inc. - "The Identification of Neurological Disorders in NFL Players"
ACCESSWIRE - Tue Sep 16, 8:32AM CDT
New York, NY / September 16, 2014 / Aethlon Medical Inc. (NASDAQ:OTCQB:AEMD) today published a new blog post on The Chairman's Blog, written by the Company's Chairman and Chief Executive Officer, James A Joyce. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.
Aethlon Medical Inc. - "The Ebola, Dengue, Enterovirus, and Chikungunya Outbreaks"
ACCESSWIRE - Wed Sep 10, 8:15AM CDT
New York, NY / September 10, 2014 / Aethlon Medical Inc. (NASDAQ:OTCQB:AEMD) today published a new blog post on The Chairman's Blog, written by the Company's Chairman and Chief Executive Officer, James A Joyce. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.
Aethlon Medical, Inc. Launches Digital Corporate Communication Channels
PR Newswire - Wed Sep 10, 8:01AM CDT
Aethlon Medical, Inc., (NASDAQ:OTCQB: AEMD), the pioneer in developing targeted therapeutic devices to address infectious disease, cancer and other life-threatening conditions, announced today a suite of online corporate communication channels to maintain on-going direct communication with shareholders and other interested parties. The Company has launched official portals on social media channels including Facebook, Twitter, LinkedIn, Google+, YouTube and The Chairman's Blog.
Aethlon Medical and Exosome Sciences Announce the Advancement of a Broad-Spectrum Cancer Detection and Monitoring Platform
PR Newswire - Mon Sep 08, 7:31AM CDT
Aethlon Medical, Inc. (NASDAQ:OTCQB:AEMD), and its diagnostic subsidiary, Exosome Sciences, Inc. (ESI), announced today that ESI researchers have developed and initially validated a lectin-based diagnostic platform that is able to isolate exosome-based biomarkers underlying a broad-spectrum of oncology indications. Aethlon Medical develops targeted therapeutic devices to address infectious disease, cancer and other life-threatening conditions. ESI develops exosome-based solutions to diagnose and monitor cancer and neurodegenerative disorders.
Aethlon Medical Announces Receipt of IRB Approval to Initiate Hemopurifier® Clinical Studies
PR Newswire - Tue Sep 02, 8:30AM CDT
Aethlon Medical, Inc. (NASDAQ:OTCQB: AEMD), the pioneer in developing targeted therapeutic devices to address infectious disease, cancer and other life-threatening conditions, announced today that it has received independent internal review board (IRB) approval to initiate human clinical studies of Hemopurifier® therapy at DaVita MedCenter Dialysis located in Houston, Texas.
Aethlon Medical (AEMD) CEO Note: A Novel Strategy To Address Ebola
PR Newswire - Wed Aug 06, 8:30AM CDT
Aethlon Medical, Inc. (OTCQB: AEMD), today released the following note authored by its Chairman and CEO, Jim Joyce.
Companies Chasing Gold Nugget of Immuno-Oncology Like Never Before
ACCESSWIRE - Thu Jun 26, 8:37AM CDT
WHITEFISH, MT / June 26, 2014 / Probably the most explosive field in biotechnology right now is that of immuno-oncology. The field is predicated on the concept that the body's immune system can be augmented or taught to modulate cancer without the use of toxic chemotherapy agents and radiation, the standard of care today worldwide. A few years ago, the immuno-oncology research was relatively non-existent, but now it's one of the hottest around with some big pharmas making it a primary directive. Last year, Merck & Co. (NYSE: MRK) brought back Roger Perlmutter, a man with an extensive background in immunology, for a second tour with the company, this time as EVP and President of Merck Research Laboratories, to shepherd a new path for Merck focused on oncology at the research level with an emphasis on immuno-oncology. Last week, Merck enlisted MorphoSys AG in a partnership to develop therapeutic antibodies against immune checkpoints. The antibody experts at MorphoSys are in high demand, inking development agreements with Celgene (NASDAQ: CELG), GlaxoSmithKline (NYSE: GSK), Novartis (NYSE: NVS) and more to develop antibodies to support the human immune system against cancer.
Aethlon Medical Announces Online Access to Infectious Disease and Cancer Therapy Presentation
PR Newswire - Wed Jun 25, 8:30AM CDT
Aethlon Medical, Inc. (OTCQB: AEMD), the pioneer in creating medical devices that target unmet therapeutic needs in infectious disease and cancer, announced today that the presentation made by Company Chairman and CEO, Jim Joyce at The Wall Street Analyst Forum on June 19th, is now available at www.aethlonmedical.com. A link to Mr. Joyce's presentation, including both the audio and slide presentation, is accessible at http://aethlonmedical.investorroom.com/index.php?s=19. Once the page has been launched, click on the "listen to the webcast" icon.
Aethlon Medical to Present at The Wall Street Analyst Forum
PR Newswire - Tue Jun 17, 11:53AM CDT
Aethlon Medical, Inc. (OTCQX:AEMD), the pioneer in developing selective therapeutic filtration devices to address infectious disease, cancer and other life-threatening conditions, announced today that the Company's Chairman and Chief Executive Officer, Jim Joyce, will present at The Wall Street Analyst Forum 25th Annual Institutional Investor Conference on Thursday, June 19th, at 12:05 PM EDT. Mr. Joyce's presentation will include an update on a forthcoming FDA-cleared study of the Aethlon Hemopurifier®, a review of the Company's cancer programs, and a progress report on Exosome Sciences, Inc., a diagnostic subsidiary recently launched by the Company.
Aethlon Medical and Exosome Sciences Expand Brain Research Discoveries to Include Isolation of Glioblastoma Biomarker and Therapeutic Target
PR Newswire - Wed Mar 19, 8:29AM CDT
Aethlon Medical, Inc. (OTCQX:AEMD), and its diagnostic subsidiary, Exosome Sciences, Inc. (ESI), announced today that researchers have isolated brain-derived exosomes released into the bloodstream from aggressive brain tumors. Through the use of proprietary size exclusion/lectin/antibody-capture techniques, the Aethlon-ESI research team was able to identify, quantify, and characterize circulating Glioblastoma multiforme (GBM) exosomes, which hold promise as both a disease biomarker and therapeutic target as GBM exosomes are shed into the circulatory system to promote tumor growth and stimulate angiogenesis.
Breakthroughs on the Horizon for CTE and Other Neurodegenerative Diseases
ACCESSWIRE - Thu Mar 13, 12:21PM CDT
Whitefish MT / March 13, 2014 / The quest to address long-term neurodegenerative problems associated with traumatic brain injury (TBI) and concussions has received plenty of attention recently, in part because of high profile athletes raising awareness and also because of some breakthrough research by Boston University and the University of California at Los Angeles. With any advancement come arguments on both sides of the debate about the accuracy of statements without extensive clinical research, and the sobering reality is that there still are no reliable treatments for diseases like Alzheimer's disease and chronic traumatic encephalopathy (CTE). All scientific posturing and argumentative rhetoric aside, the fact that companies are making strides in diagnostics and more resources are being devoted to these areas of tremendous unmet medical need are reason for optimism as there are new paths being carved in the evolution of new treatments.
Discovery Could Lead to Major Breakthrough in Alzheimer's Disease and Other Brain Disorders
ACCESSWIRE - Wed Mar 05, 12:30PM CST
Whitefish, MT / March 5, 2014 / Some leading scientists are making strides like never before in research for debilitating and deadly diseases, such as Alzheimer's Disease (AD), Chronic Traumatic Encephalopathy (CTE) and Traumatic Brain Injury (TBI). Currently, people afflicted with these conditions have little hope to avert disease progression and, sadly, death. There is reason for optimism, though, with hundreds of organizations working on new treatments and diagnostics, including Neuralstem (NYSE MKT: CUR), Thermo Fisher Scientific (NYSE: TMO) and Aethlon Medical (OTCBB: AEMD).
Aethlon Medical and Exosome Sciences Announce Brain Research Discoveries
PR Newswire - Wed Mar 05, 7:29AM CST
Aethlon Medical, Inc. (OTCQX:AEMD), and its diagnostic subsidiary, Exosome Sciences, Inc. (ESI), announced today that its researchers have successfully isolated brain-specific biomarkers associated with a variety of neurodegenerative disorders. The discoveries could have implications in the diagnosis, monitoring and treatment of Alzheimer's Disease (AD), Chronic Traumatic Encephalopathy (CTE) and Traumatic Brain Injury (TBI). Aethlon Medical develops therapeutic filtration devices to address infectious disease, cancer and other life-threatening conditions. ESI develops exosome-based solutions to diagnose and monitor acute and chronic conditions.
Aethlon Medical partners with DaVita Clinical Research to support the feasibility & pivotal study of Aethlon Hemopurifier
M2 - Thu Feb 27, 4:21AM CST
Therapeutic filtration company Aethlon Medical (OTC BB:AEMD) said on Wednesday that it has entered into a non-exclusive agreement to provide clinical management services to support the forthcoming studies of the Aethlon Hemopurifier.
Aethlon Medical Expands Clinical Network Through DaVita Agreement
ACCESSWIRE - Wed Feb 26, 2:01PM CST
Aethlon Medical, Inc. (OTC: AEMD), the pioneer in developing selective therapeutic filtration devices to address infectious disease, cancer and other life-threatening conditions, recently signed an agreement with DaVita Clinical Research (DCR) to support upcoming studies of its Aethlon Hemopurifier®. With experience conducting more than 300 early phase clinical trials through a network of more than 150 investigative physicians, DCR is uniquely positioned to help Aethlon Medical advance its unique Hemopurifier technology. DCR's numerous locations could enable Aethlon's trials to advance more quickly than they would if they were conducted in one clinical site.
Aethlon Medical® Announces Agreement with DaVita Clinical Research®
PR Newswire - Wed Feb 26, 7:03AM CST
Aethlon Medical, Inc. (OTCQX:AEMD), the pioneer in developing selective therapeutic filtration devices to address infectious disease, cancer and other life-threatening conditions, announced today that that it has reached an agreement in principle with DaVita Clinical Research® (DCR) to provide clinical management services that will support forthcoming studies of the Aethlon Hemopurifier®. The Hemopurifier® is a first-in-class therapeutic device that targets the rapid elimination of circulating viruses and tumor-secreted exosomes that suppress the immune system of cancer patients.
comScore to Appoint Serge Matta Chief Executive Officer
PR Newswire - Tue Feb 11, 6:00AM CST
comScore, Inc. (NASDAQ: SCOR) today announced that its Board of Directors has appointed Serge Matta as Chief Executive Officer, effective March 1, 2014. Concurrently, Dr. Magid Abraham, comScore's co-founder and current Chief Executive Officer, will become Executive Chairman of the Board of Directors. Gian Fulgoni, comScore's co-founder and current Executive Chairman of the Board of Directors, will become Chairman Emeritus, remaining on the Company's Board of Directors and maintaining his current external-facing industry role on behalf of comScore.
New Sonatype Software Protects The World's Enterprise Software Applications From Security, Compliance, And Licensing Threats
PR Newswire - Wed Jan 29, 1:37PM CST
Sonatype, the software company that enables developers to rapidly build secure software while also eliminating compliance and licensing risk, today released a new version of its Component Lifecycle Management (CLM) software.
Travelocity's Long Weekend Sale Encourages Travelers To Escape The Winter Blues
PR Newswire - Wed Jan 29, 6:19AM CST
It's only January but residents from Dallas to New York City have already been hit with heavy snow, blizzard conditions and freezing temperatures. To combat the winter blues, Travelocity has launched its "Go and Love the Long Weekend" sale, encouraging travelers to make the most of the upcoming Presidents Day holiday with deals on wonderful warm weather getaways.
Alleghany Corporation To Announce Fourth Quarter and Fiscal Year 2013 Results On February 25, 2014
PR Newswire - Fri Jan 24, 11:31AM CST
Alleghany Corporation (NYSE-Y) will release its financial results for the fourth quarter and 2013 fiscal year after the market closes on Tuesday, February 25, 2014. In conjunction with the release, Alleghany will post its financial supplement to the company's web-site at www.alleghany.com.
Aethlon Medical Inc. - "The Identification of Neurological Disorders in NFL Players"
ACCESSWIRE - Tue Sep 16, 8:32AM CDT
New York, NY / September 16, 2014 / Aethlon Medical Inc. (NASDAQ:OTCQB:AEMD) today published a new blog post on The Chairman's Blog, written by the Company's Chairman and Chief Executive Officer, James A Joyce. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.
Aethlon Medical Inc. - "The Ebola, Dengue, Enterovirus, and Chikungunya Outbreaks"
ACCESSWIRE - Wed Sep 10, 8:15AM CDT
New York, NY / September 10, 2014 / Aethlon Medical Inc. (NASDAQ:OTCQB:AEMD) today published a new blog post on The Chairman's Blog, written by the Company's Chairman and Chief Executive Officer, James A Joyce. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.
Aethlon Medical, Inc. Launches Digital Corporate Communication Channels
PR Newswire - Wed Sep 10, 8:01AM CDT
Aethlon Medical, Inc., (NASDAQ:OTCQB: AEMD), the pioneer in developing targeted therapeutic devices to address infectious disease, cancer and other life-threatening conditions, announced today a suite of online corporate communication channels to maintain on-going direct communication with shareholders and other interested parties. The Company has launched official portals on social media channels including Facebook, Twitter, LinkedIn, Google+, YouTube and The Chairman's Blog.
Aethlon Medical and Exosome Sciences Announce the Advancement of a Broad-Spectrum Cancer Detection and Monitoring Platform
PR Newswire - Mon Sep 08, 7:31AM CDT
Aethlon Medical, Inc. (NASDAQ:OTCQB:AEMD), and its diagnostic subsidiary, Exosome Sciences, Inc. (ESI), announced today that ESI researchers have developed and initially validated a lectin-based diagnostic platform that is able to isolate exosome-based biomarkers underlying a broad-spectrum of oncology indications. Aethlon Medical develops targeted therapeutic devices to address infectious disease, cancer and other life-threatening conditions. ESI develops exosome-based solutions to diagnose and monitor cancer and neurodegenerative disorders.
Aethlon Medical Announces Receipt of IRB Approval to Initiate Hemopurifier® Clinical Studies
PR Newswire - Tue Sep 02, 8:30AM CDT
Aethlon Medical, Inc. (NASDAQ:OTCQB: AEMD), the pioneer in developing targeted therapeutic devices to address infectious disease, cancer and other life-threatening conditions, announced today that it has received independent internal review board (IRB) approval to initiate human clinical studies of Hemopurifier® therapy at DaVita MedCenter Dialysis located in Houston, Texas.
Aethlon Medical (AEMD) CEO Note: A Novel Strategy To Address Ebola
PR Newswire - Wed Aug 06, 8:30AM CDT
Aethlon Medical, Inc. (OTCQB: AEMD), today released the following note authored by its Chairman and CEO, Jim Joyce.
Companies Chasing Gold Nugget of Immuno-Oncology Like Never Before
ACCESSWIRE - Thu Jun 26, 8:37AM CDT
WHITEFISH, MT / June 26, 2014 / Probably the most explosive field in biotechnology right now is that of immuno-oncology. The field is predicated on the concept that the body's immune system can be augmented or taught to modulate cancer without the use of toxic chemotherapy agents and radiation, the standard of care today worldwide. A few years ago, the immuno-oncology research was relatively non-existent, but now it's one of the hottest around with some big pharmas making it a primary directive. Last year, Merck & Co. (NYSE: MRK) brought back Roger Perlmutter, a man with an extensive background in immunology, for a second tour with the company, this time as EVP and President of Merck Research Laboratories, to shepherd a new path for Merck focused on oncology at the research level with an emphasis on immuno-oncology. Last week, Merck enlisted MorphoSys AG in a partnership to develop therapeutic antibodies against immune checkpoints. The antibody experts at MorphoSys are in high demand, inking development agreements with Celgene (NASDAQ: CELG), GlaxoSmithKline (NYSE: GSK), Novartis (NYSE: NVS) and more to develop antibodies to support the human immune system against cancer.
Aethlon Medical Announces Online Access to Infectious Disease and Cancer Therapy Presentation
PR Newswire - Wed Jun 25, 8:30AM CDT
Aethlon Medical, Inc. (OTCQB: AEMD), the pioneer in creating medical devices that target unmet therapeutic needs in infectious disease and cancer, announced today that the presentation made by Company Chairman and CEO, Jim Joyce at The Wall Street Analyst Forum on June 19th, is now available at www.aethlonmedical.com. A link to Mr. Joyce's presentation, including both the audio and slide presentation, is accessible at http://aethlonmedical.investorroom.com/index.php?s=19. Once the page has been launched, click on the "listen to the webcast" icon.
Aethlon Medical to Present at The Wall Street Analyst Forum
PR Newswire - Tue Jun 17, 11:53AM CDT
Aethlon Medical, Inc. (OTCQX:AEMD), the pioneer in developing selective therapeutic filtration devices to address infectious disease, cancer and other life-threatening conditions, announced today that the Company's Chairman and Chief Executive Officer, Jim Joyce, will present at The Wall Street Analyst Forum 25th Annual Institutional Investor Conference on Thursday, June 19th, at 12:05 PM EDT. Mr. Joyce's presentation will include an update on a forthcoming FDA-cleared study of the Aethlon Hemopurifier®, a review of the Company's cancer programs, and a progress report on Exosome Sciences, Inc., a diagnostic subsidiary recently launched by the Company.
Aethlon Medical and Exosome Sciences Expand Brain Research Discoveries to Include Isolation of Glioblastoma Biomarker and Therapeutic Target
PR Newswire - Wed Mar 19, 8:29AM CDT
Aethlon Medical, Inc. (OTCQX:AEMD), and its diagnostic subsidiary, Exosome Sciences, Inc. (ESI), announced today that researchers have isolated brain-derived exosomes released into the bloodstream from aggressive brain tumors. Through the use of proprietary size exclusion/lectin/antibody-capture techniques, the Aethlon-ESI research team was able to identify, quantify, and characterize circulating Glioblastoma multiforme (GBM) exosomes, which hold promise as both a disease biomarker and therapeutic target as GBM exosomes are shed into the circulatory system to promote tumor growth and stimulate angiogenesis.
Breakthroughs on the Horizon for CTE and Other Neurodegenerative Diseases
ACCESSWIRE - Thu Mar 13, 12:21PM CDT
Whitefish MT / March 13, 2014 / The quest to address long-term neurodegenerative problems associated with traumatic brain injury (TBI) and concussions has received plenty of attention recently, in part because of high profile athletes raising awareness and also because of some breakthrough research by Boston University and the University of California at Los Angeles. With any advancement come arguments on both sides of the debate about the accuracy of statements without extensive clinical research, and the sobering reality is that there still are no reliable treatments for diseases like Alzheimer's disease and chronic traumatic encephalopathy (CTE). All scientific posturing and argumentative rhetoric aside, the fact that companies are making strides in diagnostics and more resources are being devoted to these areas of tremendous unmet medical need are reason for optimism as there are new paths being carved in the evolution of new treatments.
Discovery Could Lead to Major Breakthrough in Alzheimer's Disease and Other Brain Disorders
ACCESSWIRE - Wed Mar 05, 12:30PM CST
Whitefish, MT / March 5, 2014 / Some leading scientists are making strides like never before in research for debilitating and deadly diseases, such as Alzheimer's Disease (AD), Chronic Traumatic Encephalopathy (CTE) and Traumatic Brain Injury (TBI). Currently, people afflicted with these conditions have little hope to avert disease progression and, sadly, death. There is reason for optimism, though, with hundreds of organizations working on new treatments and diagnostics, including Neuralstem (NYSE MKT: CUR), Thermo Fisher Scientific (NYSE: TMO) and Aethlon Medical (OTCBB: AEMD).
Aethlon Medical and Exosome Sciences Announce Brain Research Discoveries
PR Newswire - Wed Mar 05, 7:29AM CST
Aethlon Medical, Inc. (OTCQX:AEMD), and its diagnostic subsidiary, Exosome Sciences, Inc. (ESI), announced today that its researchers have successfully isolated brain-specific biomarkers associated with a variety of neurodegenerative disorders. The discoveries could have implications in the diagnosis, monitoring and treatment of Alzheimer's Disease (AD), Chronic Traumatic Encephalopathy (CTE) and Traumatic Brain Injury (TBI). Aethlon Medical develops therapeutic filtration devices to address infectious disease, cancer and other life-threatening conditions. ESI develops exosome-based solutions to diagnose and monitor acute and chronic conditions.
Aethlon Medical partners with DaVita Clinical Research to support the feasibility & pivotal study of Aethlon Hemopurifier
M2 - Thu Feb 27, 4:21AM CST
Therapeutic filtration company Aethlon Medical (OTC BB:AEMD) said on Wednesday that it has entered into a non-exclusive agreement to provide clinical management services to support the forthcoming studies of the Aethlon Hemopurifier.
Aethlon Medical Expands Clinical Network Through DaVita Agreement
ACCESSWIRE - Wed Feb 26, 2:01PM CST
Aethlon Medical, Inc. (OTC: AEMD), the pioneer in developing selective therapeutic filtration devices to address infectious disease, cancer and other life-threatening conditions, recently signed an agreement with DaVita Clinical Research (DCR) to support upcoming studies of its Aethlon Hemopurifier®. With experience conducting more than 300 early phase clinical trials through a network of more than 150 investigative physicians, DCR is uniquely positioned to help Aethlon Medical advance its unique Hemopurifier technology. DCR's numerous locations could enable Aethlon's trials to advance more quickly than they would if they were conducted in one clinical site.
Aethlon Medical® Announces Agreement with DaVita Clinical Research®
PR Newswire - Wed Feb 26, 7:03AM CST
Aethlon Medical, Inc. (OTCQX:AEMD), the pioneer in developing selective therapeutic filtration devices to address infectious disease, cancer and other life-threatening conditions, announced today that that it has reached an agreement in principle with DaVita Clinical Research® (DCR) to provide clinical management services that will support forthcoming studies of the Aethlon Hemopurifier®. The Hemopurifier® is a first-in-class therapeutic device that targets the rapid elimination of circulating viruses and tumor-secreted exosomes that suppress the immune system of cancer patients.
comScore to Appoint Serge Matta Chief Executive Officer
PR Newswire - Tue Feb 11, 6:00AM CST
comScore, Inc. (NASDAQ: SCOR) today announced that its Board of Directors has appointed Serge Matta as Chief Executive Officer, effective March 1, 2014. Concurrently, Dr. Magid Abraham, comScore's co-founder and current Chief Executive Officer, will become Executive Chairman of the Board of Directors. Gian Fulgoni, comScore's co-founder and current Executive Chairman of the Board of Directors, will become Chairman Emeritus, remaining on the Company's Board of Directors and maintaining his current external-facing industry role on behalf of comScore.
New Sonatype Software Protects The World's Enterprise Software Applications From Security, Compliance, And Licensing Threats
PR Newswire - Wed Jan 29, 1:37PM CST
Sonatype, the software company that enables developers to rapidly build secure software while also eliminating compliance and licensing risk, today released a new version of its Component Lifecycle Management (CLM) software.
Travelocity's Long Weekend Sale Encourages Travelers To Escape The Winter Blues
PR Newswire - Wed Jan 29, 6:19AM CST
It's only January but residents from Dallas to New York City have already been hit with heavy snow, blizzard conditions and freezing temperatures. To combat the winter blues, Travelocity has launched its "Go and Love the Long Weekend" sale, encouraging travelers to make the most of the upcoming Presidents Day holiday with deals on wonderful warm weather getaways.
Alleghany Corporation To Announce Fourth Quarter and Fiscal Year 2013 Results On February 25, 2014
PR Newswire - Fri Jan 24, 11:31AM CST
Alleghany Corporation (NYSE-Y) will release its financial results for the fourth quarter and 2013 fiscal year after the market closes on Tuesday, February 25, 2014. In conjunction with the release, Alleghany will post its financial supplement to the company's web-site at www.alleghany.com.
